Lille University Hospital uses ultra-innovative technology: the very high-speed sequencer.
The aim is to detect genetic abnormalities to improve patient care. This equipment will be used for the benefit of patients with genetic disease or cancer.
A project supported by ARS Hauts-de-France in collaboration with the CHU Amiens-Picardie.
After 10 years of collaboration between the Lille University Hospital and Evosciences, we are particularly happy to support this initiative. A very high speed Illumina NovaSeq 6000 sequencer financed with a flexible rental solution through Evosciences.
The goal of the Department of Biology and Genetic Pathology is to detect genetic abnormalities and improve the management of patients with genetic diseases or cancer by systematic analysis of the exome.
About the Lille University Hospital.
With nearly 16,000 professionals, the Lille University Hospital Centre is one of the most important public health care facility in northern Europe. A benchmark, teaching, innovation and research hospital, it serves the 6 million inhabitants of the Hauts-de-France region.
Open 24/7, the hospital guarantees equal access to care to all those who need it. Hospitalization or outpatient care for 1.4 million patients each year, with expertise and kindness. The Lille University Hospital offers local care, but also reference and resource thanks to a state-of-the-art medico-technical platform and medical expertise specializing in many areas.
New premises for NovAliX with the takeover of Sanofi Strasbourg and an agreement signed with Janssen.
New premises for Stephan Jenn, president of NovAliX and his team in Val de Reuil and Strasbourg to increase its production capacities.
NovAliX has also signed an agreement with Janssen and becomes one of its main research providers.
Congratulations to Stephan Jenn and his team for this important development. Evosciences remains more than ever Novalix’s partner to finance its laboratory equipment and help it grow.
NovAliX is a CRO focused on drug discovery, based on the transfer of academic knowledge into industrial applications of interest.
NovAliX is a private company located near Strasbourg (France) and owned by its Management team, its scientific founders and its employees.
After two decades of excellent results in chemistry and biophysics for its customers, NovAliX has become a supplier recognized for its expertise with its partners ranging from virtual companies to global players.
NovAliX provides externalized support that complements the internal capacities of its partners, from biopharmaceutical companies to venture capital companies, while developing alliances adapted to each need. NovAliX pioneered the concept and practice of insourcing in Europe but has also engaged in risk-sharing collaborations with biotechnology investors. An alliance with a large pharmaceutical company has also been entered into to co-develop DNA encoded library technology.
Sanofi, a healthcare leader in France and around the world.
Every day at Sanofi France, 25,000 women and men join forces with passion to transform scientific advances into therapeutic solutions so that everyone can live their lives to the fullest. Faced with health challenges and the complexity of diseases, this mission can be summed up as follows: prevent, treat and cure diseases.
Evosciences, official partner of Sanofi for the financing of its scientific equipment.
The main mission of Evosciences is to enable its clients to optimize the use of their scientific equipment platforms through their funding and our remarketing services.
In November 2003, Evosciences became the official partner of Sanofi.
A long-standing partnership confirmed again by Sanofi in 2019.
To be part of this partnership is unique. Evosciences is therefore very proud to support one of the most creative pharmaceutical companies in the protection of human beings with its expertise and flexible financial solutions in the scientific equipment market.
A big thank you to the scientific purchasing team, the finance department and of course, to all laboratory and scientific managers for their trust.